

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

SUSPENSION OF TRADING

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company announces that the Securities and Futures Commission (“**SFC**”) has on 6 October 2017 issued a direction under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (“**Rule 8(1) Direction**”) to suspend trading in the shares of the Company with effect from 9:00 a.m. on 6 October 2017 as it appears to the SFC that:

- (i) the Company’s announcements dated 14 February 2015, 20 March 2015, 26 June 2015 and 16 July 2015 in relation to the acquisition of 50% interest in Saike International Medical Group Limited and the Company’s announcements dated 5 December 2016 and 14 March 2017 in relation to the acquisition of 15% interest in Eternal Charm International Limited (now known as “WinHealth International Company Limited”) may have contained materially false, incomplete or misleading information;
- (ii) it is necessary or expedient to do so in the interest of maintaining an orderly and fair market in the shares of the Company; and
- (iii) it is in the interest of the investing public or in the public interest, or it is appropriate for the protection of investors generally or for the protection of investors in the shares of the Company to do so.

The Company is entitled to make representations in respect of the Rule 8(1) Direction to the SFC under Section 9 of the Securities and Futures (Stock Market Listing) Rules. The Company is seeking further legal advice as to its rights, as well as how to address and resolve the SFC's concerns going forward and resume trading of the shares.

The Company will make further announcement(s) as and when appropriate.

On behalf of the Board
New Ray Medicine International Holding Limited
Zhou Ling
Chairman & Executive Director

Hong Kong, 6 October 2017

As of the date of this announcement, the executive Directors are Mr. Zhou Ling and Ms. Yang Fang; and the independent non-executive Directors are Mr. Ho Hau Cheung, SBS, MH, Mr. Leung Chi Kin and Ms. Li Sin Ming, Ivy.